July 6, 2021

Austin, Texas – The discovery of the genetic origins of Cannabinoid Hyperemesis Syndrome (CHS) is a major step forward in diagnosing and treating this previously enigmatic and poorly recognized, yet increasingly common condition triggered by high-THC consumption. Symptoms of CHS include intractable nausea, cyclic vomiting, abdominal pain, and hot bathing behavior in episodes that can last for several weeks and represent a grievous health and financial burden to its victims.  This study represents the largest patient cohort of CHS patients examined to date, and first to note associated mutations in genes affecting neurotransmitters, the endocannabinoid system (ECS), and the cytochrome P450 complex associated with cannabinoid metabolism.

“These important preliminary findings, contribute to the growing body of knowledge, stimulate additional investigation, help elucidate the pathophysiology of CHS and, ultimately, direct future treatment,” says chief investigator Ethan Russo, MD.

The scientific team was led by Dr. Russo, a world-renowned medical cannabis expert, and Len May, a leader in the field of endocannabinoid system (ECS) genomics. Dr. Russo is a board-certified neurologist, a psychopharmacology researcher, the CEO of CReDO Science, and a prolific author.

The scientific team, which also includes naturopathic physician and cannabis scientist Chris Spooner, Ryan Leslie, and Nishi Whiteley, is “focused on using this data to do a larger clinical study that will create an industry standard for CHS diagnostics.”

Read the full article at Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation (liebertpub.com). 

CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.

October 26, 2020

Austin, Texas – CReDO Science (https://credo-science.com) is proud to announce the launch of a formulation service for therapeutic cannabis-based products. This would include the crafting of unique and customized supplements for over-the-counter sales, and provision of formulations for pharmaceutical development and regulatory approval by the US Food and Drug Administration (FDA), Health Canada (HC), and European Medicines Agency (EMA).

CReDO Science, CEO, cannabis research and drug development pioneer Dr. Ethan Russo says, “Our aim is to provide blueprints for synergistic preparations of cannabis extracts and components that leverage the entourage effect of the many therapeutic compounds in cannabis. Only then can the full potential of cannabis be realized to provide medicines that are safe, effective and consistent.” 

Dr. Russo is a board-certified neurologist and the author/co-author of over 50 peer-reviewed journal articles and seven books on medical cannabis and the endocannabinoid system. A veteran of GW Pharmaceuticals, Dr. Ethan Russo served as the Medical Monitor and Study Physician for the clinical trials of Sativex® and Epidiolex®, the first cannabis-based pharmaceuticals to market.

A pioneer in the area of medical cannabis research and drug development, Dr. Russo understands deeply the intricacies of formulating botanical medicines and the regulatory approval pathways and requirements. As one of the few people in the world who has helped secure FDA approval for a cannabis plant-based pharmaceutical, he has participated in over 20 clinical trials for cannabis-based pharmaceuticals designed for treatment of amyotrophic lateral sclerosis, multiple sclerosis, neuropathic pain, cancer pain, autism, and epilepsy.

“Due to a variety of factors including prohibition and political barriers to research, the available literature on therapeutic applications of cannabis has frequently resulted in mixed or negative results that can be attributed to utilization of unstandardized material without consideration to its biochemical composition. It rarely has been the case that randomized controlled trials, the gold standard of medical proof of safety and efficacy, have been undertaken with truly optimized cannabis formulations,” laments Dr. Russo. CReDO Science wants to change that.

Companies will find that Dr. Russo’s expertise will provide considerable cost savings by significantly reducing product development timelines and increasing product value by creating more competitive products. Such a formulation service is necessary to achieve CReDO Science’s mission of “Making Cannabis Safer and Better.”

Click here to download the pdf version of the press release.

Contact: Nishi Whiteley, nw at credo-science dot com